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Alzheimer’s disease (AD) is recognized to have a long presymptomatic period, during which there is progressive
accumulation of molecular pathology, followed by inexorable neuronal damage. The ability to identify presymptomatic
individuals with evidence of neurodegenerative change, to stage their disease, and to track progressive changes
will be important for early diagnosis and for prevention trials. Despite recent advances, particularly in magnetic
resonance imaging, our ability to identify early neurodegenerative changes reliably is limited. The development
of diffusion-weighted magnetic resonance imaging, which is sensitive to microstructural changes not visible with
conventional volumetric techniques, has led to a number of diffusion imaging studies in AD; these have largely
focused on white matter changes. However, in AD cerebral grey matter is affected very early, with pathological
studies suggesting that grey matter changes predate those in white matter. In this article we review the growing
number of studies that assess grey matter diffusivity changes in AD. Although use of the technique is still at a
relatively early stage, results so far have been promising. Initial studies identified changes in diffusion measures in
the hippocampi of patients with mild cognitive impairment, which predated macroscopic volume loss, with positive
predictive value for progression to AD dementia. More recent studies have identified abnormalities in multiple
neocortical areas (particularly the posterior cingulate) at various stages of disease progression. Studies of patients
who carry genetic mutations predisposing to autosomal dominant familial AD have shown cortical and subcortical grey
matter diffusivity changes several years before the expected onset of the first clinical symptoms. The technique is not
without potential methodological difficulties, especially relating to partial volume effects, although recent advances
appear to be reducing such issues. Going forward, further utilization of grey matter diffusion measurements in AD may
improve our understanding with regards to the timing and nature of the earliest presymptomatic neurodegenerative
changes. This imaging technique may also be useful in comparing and contrasting subtle variations in different disease
subgroups, and as a sensitive outcome measure for presymptomatic clinical trials in AD and other neurodegenerative
diseases.Introduction
There is growing evidence in Alzheimer’s disease (AD)
of a long latency period, with pathological changes be-
ginning decades before symptom onset [1, 2]. During this
period there is progressive accumulation of molecular
pathology, followed by increasing and inexorable neur-
onal damage. A ‘self-perpetuating’ aspect of neurode-
generation that is difficult to slow once established may
account, at least in part, for notable clinical trial failures* Correspondence: philip.weston.11@ucl.ac.uk
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creativecommons.org/publicdomain/zero/1.0/[3, 4]. There is increasing recognition that our best chance
of maintaining brain function may be to offer therapies as
early as possible, when the minimum of irretrievable neur-
onal loss has occurred, and when there is potential to
prevent or delay the onset of cognitive decline [5]. In
order to do this, methods are needed to identify indi-
viduals at risk, to stage their disease, and to track pro-
gression with sensitive and robust measures [6].
Significant advances in AD biomarkers and neuroimag-
ing measures, in particular, have been made over the past
two decades. These measures have helped improve both
our understanding of the disease and our ability to detectrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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ical settings. The earliest magnetic resonance imaging
(MRI) studies focused on macroscopic brain changes, with
the best established symptomatic and late presymptomatic
marker being hippocampal atrophy [7–9]. However, sub-
sequent studies have shown that the predictive value of
such measures, particularly when applied as a single
cross-sectional measure at the level of the individual, is
limited prior to the onset of dementia [10, 11]. More re-
cently, automated techniques to measure cortical thick-
ness have shown early changes in multiple cerebral areas
[12–14]. However, the utility of these techniques in the
earliest presymptomatic stages is again uncertain. There
currently appears to be a gap of several years between
the appearance of the earliest pathological changes (for
example, of amyloid deposition using positron emission
tomography or cerebrospinal fluid (CSF) measures) and
the point when conventional macroscopic imaging tech-
niques are first able to detect degenerative change reliably.
In recent years, there have been great advances in
diffusion-weighted imaging [15]. The key benefit of diffu-
sion MRI is the ability to observe changes at the micro-
scopic level (Fig. 1). The breakdown of microstructural
barriers, such as myelin, cell membranes and intracellular
organelles, which would normally restrict the Brownian
motion of water molecules, results in a measureable
difference in the diffusion of water molecules [16]. Such
changes are not visible on conventional structural MRI
sequences, and several studies suggest they predate macro-
scopic atrophy [17–19].
The initial focus of diffusion-weighted MRI in neuro-
degeneration research was on the study of white matter
tract integrity, using the diffusion tensor model [16]. This
was commonly assessed using the metric of fractionalFig. 1 Coronal view of a T1-weighted magnetic resonance image of the brai
the cortical thickness (center); on the right is a schematic representation of a
cells, dependent on the integrity of the cell structureanisotropy, which describes the directional coherence
of diffusion along fibers. However, whilst studying the
breakdown of white matter structural connectivity has
helped broaden our understanding of AD, the specific
mechanisms underlying white matter damage remain
unclear [19–21]. One suggestion has been that white
matter changes are the result of Wallerian degeneration, a
downstream consequence following the earlier loss of cor-
tical neurons [20]. Also, from a histopathological stand-
point, AD is primarily a cortical disease, particularly in
the early stages [22]. Grey matter changes have also been
shown to correlate more closely with clinical abnormal-
ities than white matter changes [23], and have a closer link
to clinical symptoms than amyloid deposition [2, 24].
The application of diffusion imaging for the detection
of microscopic grey matter abnormalities may therefore
be a potentially powerful tool in identifying the earliest
AD changes (Fig. 2).
A growing body of literature is emerging that describes
the use of diffusion-weighted MRI to detect microscopic
grey matter changes in a number of neurodegenerative
disorders. Indeed in one such condition - Creutzfeldt-Jakob
disease (CJD) - detection of diffusivity changes in grey mat-
ter has now become the gold standard in clinical diagnostic
practice [25, 26]. Alzheimer’s disease is a less rapidly pro-
gressive condition than CJD, and so diffusivity changes
might not be as marked. However, the use of diffusion
MRI for the detection of grey matter abnormalities has
shown promise in less rapidly progressive conditions,
such as multiple sclerosis, where it was used to demon-
strate the existence of cortical grey matter damage [27].
More recently diffusion-weighted imaging of grey mat-
ter in AD has been successfully used in a number of differ-
ent studies. The majority of studies have used the metricn (left image); magnified area of cortex, with the black arrow indicating
magnified region of cortex, with water molecules diffusing within the
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Fig. 2 A graphical illustration of the sequence of biomarker changes that are thought to occur in Alzheimer's disease prior to the clinical manifestation
of dementia (adapted from the model proposed by Jack et al. [55]). An additional curve has been added (in orange) to represent where microstructural
brain changes (the earliest of which are likely to occur in the grey matter) are predicted to lie in the overall sequence. The black arrows show how the
use of magnetic resonance imaging to detect diffusivity changes in grey matter may allow significantly earlier detection of neurodegenerative change
than is possible with conventional (macro)structural imaging methods. Aβ, amyloid β; MCI, mild cognitive impairment
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gree of diffusion in all directions, as opposed to quantify-
ing directionality. It has been argued that, compared with
fractional anisotropy, MD lends itself better to the assess-
ment of cortical and subcortical grey matter, where net
diffusion may not be expected to conform to any one
specific direction [28]. As cellular microstructure breaks
down and there are fewer obstacles to diffusion, molecules
are able to diffuse more freely and MD is generally ex-
pected to increase [15]. We will now review the results
of these studies and consider both what they tell us
about the pathophysiology of AD, and how they might
be utilized in the clinical setting.
Method of systematic literature review
A literature search was conducted on PubMed in October
2014. We aimed to identify all articles that used diffusion-
weighted MRI to investigate grey matter diffusivity
changes in AD. The search [Alzheimer’s] AND [DTI OR
diffusion] AND [grey matter OR cortex] was applied. The
title and abstract of all articles identified by the search were
assessed for suitability for inclusion in the review. For all
suitable articles from the initial search, the titles and ab-
stracts of articles in their reference lists were reviewed, and
any additional suitable articles also included.
Hippocampal diffusivity
Early studies of grey matter diffusion assessed MD in
the hippocampi of patients with amnestic mild cognitive
impairment (MCI), and compared the imaging results of
those who did and did not go on to progress to clinical
AD [17, 18]. In these studies, which contained 18 (Mulleret al. [18]) and 24 (Kantarci et al. [17]) amnestic MCI pa-
tients, hippocampi were segmented manually, with care
taken to ensure that none of the surrounding CSF was in-
cluded. The studies found that those who did progress to
AD had significantly higher hippocampal MD at baseline
than those who did not. Also, compared with macroscopic
volume measurements, MD was a more sensitive pre-
dictor of progression to clinical 'AD dementia', and also
correlated significantly better with severity of episodic
memory deficits. These findings demonstrated that micro-
scopic changes are detectable within the hippocampi prior
to definite volumetric change, thus offering potential im-
provement in diagnostic sensitivity. Muller and colleagues
[29–31] went on to replicate these findings and showed
that the manual segmentation and analysis technique had
good intra-observer and inter-observer reliability.
Douaud et al. [32] used an automated voxel-wise ana-
lysis to assess both grey and white matter diffusion, again
in a cohort of amnestic MCI patients. They also found
hippocampal diffusivity to be a sensitive predictor of
progression over a 3 year follow-up period, with it being
more sensitive than any changes to white matter tracts,
and also a better predictor than CSF A-beta amyloid and
tau measurements.
Beyond the hippocampi - neocortical changes in
diffusivity
Following the finding of early hippocampal diffusivity
changes, the focus has broadened to other cortical areas.
Rose et al. [33] used whole brain voxel-wise analysis to
assess cortical changes in clinically established AD. A
number of cortical areas, beyond the hippocampi, were
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the posterior cingulate cortex (with the greatest effect
size), entorhinal cortex, amygdala, parahippocampal gyrus,
middle temporal gyrus, superior and middle frontal gyrus
and the supramarginal gyrus bilaterally; a pattern which is
similar to that seen in studies of cortical thickness [12]. A
further study used both whole brain and manually seg-
mented region of interest analyses to assess patients with
MCI and with established AD [34]. A significant trend
was seen along the trajectory from normal controls, to
MCI, to established AD, in terms of whole brain average
grey matter MD. This was contrary to volume measure-
ments, which were not able to accurately predict pro-
gression. Additionally, MD measurements in a number
of regions of interest, including hippocampi, amygdala,
parieto-occipital association cortices and frontal lobe cor-
tical areas, were found to be independently associated with
disease progression. As discussed by the study’s authors,
the observed spreading of microstructural cortical involve-
ment as the disease progresses fits well with the established
histopathological staging of AD [22].
Diffusion analysis of multiple cortical areas has dem-
onstrated some value in differentiation of different types
of dementia [35]. Compared with patients with dementia
with Lewy bodies, patients with probable AD had higher
MD in the hippocampi, parahippocampal gyri, tempero-
parietal association cortices, posterior cingulate cortex and
the precuneus. In a logistic regression model the ability to
differentiate the two diseases was significantly increased
with the addition of MD measurements compared with
volume measurements alone.
Patients with earlier stages of AD have also shown
widespread patterns of change. One study [36] of 20 pa-
tients with amnestic MCI found elevated diffusivity (with
associated reduced fractional anisotropy) compared with
controls, in a cortical distribution very similar to that de-
scribed above. Again, the most marked effects were seen
in the posterior cingulate cortex. Unfortunately, the value
of cortical diffusivity measurements, and particularly that
of the posterior cingulate, in predicting conversion from
MCI to AD was not assessed. However, the importance of
the posterior cingulate cortex in maintaining function in
multiple different cognitive domains has been confirmed
by a large cortical diffusion study of healthy individuals
and patients with different focal MCI syndromes [37].
The study found that diffusivity changes in the posterior
cingulate were independently associated with memory,
language, executive function and visuospatial function.
Familial Alzheimer’s - findings from presymptom-
atic disease
Although rare, autosomal dominant familial AD (FAD)
shares many aspects, both molecularly and clinically, with
sporadic AD [5]. Studying individuals from families affectedby FAD provides the opportunity for prospective longi-
tudinal study of individuals who are cognitively normal
but who are known to be destined to develop the disease,
thereby allowing assessment of preclinical neurodegenera-
tive changes [5]. Whilst studies using diffusion MRI in
preclinical FAD have involved relatively small samples, the
findings have been informative.
A region of interest study of presenilin 1 (PSEN1) gene
mutation carriers (n = 10) found significant differences
in hippocampal diffusivity compared with controls [38].
In the symptomatic phase, hippocampal MD was elevated,
as has been seen in sporadic AD. In the presymptomatic
phase (5.6 years, on average, prior to predicted age at
onset) hippocampal MD was also found to be abnormal
and occurred prior to change in hippocampal volume.
In addition to the hippocampal changes described above,
in a small study of PSEN1 mutation-positive individ-
uals, widespread neocortical diffusion changes were dem-
onstrated prior to the onset of symptoms [39]. These
changes were most prominent posteriorly, affecting the
precuneus, posterior cingulate cortex and inferior parietal
cortex, similar to that which has been seen in early symp-
tomatic sporadic patients [36]. This distribution differed
from symptomatic FAD patients, in whom MD changes
were observed throughout the whole cortex.
The two studies of FAD described above also showed
diffusivity changes in thalamus and caudate several years
prior to predicted symptom onset, albeit with some changes
in macroscopic volume measurements also being evident
[38, 39]. The presence of early changes in subcortical grey
matter integrity is consistent with the early subcortical
amyloid deposition observed in familial AD, and serves
to emphasize that it is not only cortical grey matter that
is affected early in the disease process [40, 41]. However,
whether assessment of similar subcortical grey matter
areas would be useful in demonstrating early changes in
sporadic AD, or whether early thalamostriatal change is
unique to familial AD, has not yet been established.
The above studies detected in vivo presymptomatic
microstructural grey matter changes in limbic cortex, neo-
cortex and subcortical grey matter structures. However,
one key finding, consistent across all of these anatomical
structures, was that the presymptomatic change in MD
was not in the direction one would have expected, in
that it was decreased rather than increased compared
with controls. This is opposite to the direction of change
observed in symptomatic AD (both familial and sporadic).
This reduction in presymptomatic MD was also associated
with marginally increased cortical thickness. Although
unexpected, and requiring further replication in larger
studies, the finding of a presymptomatic fall in MD is
very interesting. It may suggest the presence of more than
one pathological process affecting diffusion imaging changes:
the presymptomatic reduction in MD may indicate an
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occurring prior to (or coincident with and obscuring) the
onset of microstructural breakdown and macrostructural
atrophy [38, 39]. A summary of research studies assessing
grey matter diffusivity in AD is given in Table 1.
Methodological considerations
Measuring molecular diffusion in grey matter structures
is not without pitfalls. An important issue is the potential
for results to be biased by partial volume effects [18, 35].
This problem is particularly important in cortical studies
because the cortex has a thickness (generally 2 to 3 mm)
that is similar to the typical voxel diameters used in dif-
fusion imaging (2 to 2.5 mm isotropic), with the issuea
b
c
Fig. 3 A simplified schematic representation of molecular diffusion
in and around neurons, and how this may change over time in
Alzheimer’s disease (AD). a In the early presymptomatic stage water
molecules are able to diffuse normally, with the mean diffusivity
(MD) being the same as a normal healthy individual. b Evidence
from familial AD studies suggests that in the period shortly before
symptom onset the MD falls, implying that diffusion is restricted.
This restriction may be a result of cellular hypertrophy and/or
inflammation, in response to amyloid deposition in the presymptomatic
phase. c During the symptomatic phase, progressive cellular atrophy
results in a breakdown in the usual barriers to diffusion, with studies
showing an increase in MD compared with normal controls. The
effects in (c) are likely to progressively outweigh the effects in (b)
as the disease progressesbeing complicated further by the fact that the cortex has a
convoluted structure and is adjacent to CSF spaces.
There is, therefore, a danger of cortical voxels also con-
taining some CSF, with this risk increasing as the cortex
atrophies.
Investigators have addressed the issue of potential partial
voluming in a number of ways. Accurate segmentation, en-
suring the region does not include any CSF, is important
[29, 31, 33]. Setting inclusion thresholds that exclude any
voxel with an MD approaching that of CSF has also been
done [33]. However, altering the characteristics of the dis-
tribution of MD measures by thresholding based on those
same measures is questionable; this can give distinctly
non-Gaussian distributions, which are difficult to analyze
statistically. A further method used to reduce the risk of
partial voluming has been to co-register the diffusion im-
ages to a FLAIR sequence, as opposed to a T2 sequence as
is conventionally done [35, 37]. By doing this, the signal
from the CSF is suppressed, increasing the reliability of
cortical diffusivity measurements. An additional consid-
eration relates to how the diffusion image is spatially co-
registered to the segmentations of the structural scan,
which is itself not a trivial process, and can introduce
further partial voluming if not done accurately [42, 43].
A methodological development that offers potential
benefits for the measurement of grey matter diffusivity is
the recent advent of multiband MRI [44]. By simultan-
eously acquiring magnetic resonance data from multiple
slices, this technique significantly increases the acquisition
speed and offers the possibility of reducing the voxel size -
from the 2 to 2.5 mm isotropic that is currently most
common down to 1 to 1.5 mm isotropic - without having
to substantially increase the duration of the scan. This
improvement in spatial resolution significantly reduces
partial voluming, and is increasingly used [45, 46]. New
multi-shell acquisition techniques, including composite
hindered and restricted model of diffusion (CHARMED)
and neurite orientation dispersion and density imaging
(NODDI), are able to model neural tissue in terms of
multiple separate compartments (for example, intracellular,
extracellular and CSF) [47, 48]. This allows these techniques
to model the partial volume effect, which is not possible
with conventional single-shell techniques, and therefore
offers potential for more precise and reliable diffusion
metrics.
An additional factor to consider if grey matter diffusion
is to enter widespread clinical use is the significant time
and effort required to segment regions of interest manu-
ally. Grey matter diffusivity analysis would ideally be auto-
mated [49]. Such methodology has recently been used
successfully in studies of cortical and subcortical grey
matter diffusivity in AD and other neurodegenerative
conditions [38, 50, 51], and could potentially be transferred
to the clinical setting.
Table 1 A summary of AD studies that have measured grey matter diffusion changes
Study Familial or
sporadic
n Methods Main findings
Kantarci et al.
2005 [17]
Sporadic 21 MCI, 54 NC Hippocampi manually segmented.
Volume and MD measured. 36 month
clinical follow-up
Hippocampal MD better than hippocampal
volume for predicting conversion from MCI
to AD over the 36 month follow-up
Muller et al. 2005 [18] Sporadic 18 MCI, 18 NC Hippocampi manually segmented.
Volume, MD + FA measured
Increased MD in hippocampus is strongest
independent predictor of episodic memory
decline, and is more sensitive than volume loss
Fellgiebel et al.
2006 [31]
Sporadic 18 MCI Hippocampi manually segmented.
Volume and MD measured. 18 month
clinical follow-up with convertors and
non-convertors compared
Increased left hippocampal MD at baseline in
convertors compared with non-convertors
Rose et al. 2008 [33] Sporadic 13 AD, 13 NC Voxelwise GM MD analysis Elevated MD in hippocampus, amygdala,and
medial temporal, parietal, and frontal GM in
AD. Largest number of abnormal voxels in PCC
Scola et al. 2010 [34] Sporadic 21 AD, 21 MCI,
20 NC
Whole brain GM +WM MD; followed by
ROI analysis. 2 year clinical follow-up
with MCI convertors and non-convertors
compared
Trend seen over normal/MCI/AD for GM +WM MD.




Sporadic 30 AD, 30 DLB,
60 NC
ROI analysis using FLAIR diffusion imaging,
measuring MD (plus volumes) in GM
Compared to DLB, AD has elevated MD in
hippocampi, parahippocampal gyri, amygdala,
temporoparietal association cortices, PCC +




Sporadic 35 MCI Voxelwise GM MD measured, with
convertors and non-convertors
compared (36 month follow-up)
Elevated left hippocampal and amygdala MD in




Sporadic 20 MCI, 20 NC Whole-brain CTh, MD analysis on GM.
ROI analysis then applied
MCI showed increased MD in precuneus, PCC,




Familial 6 PMC, 5 SMC,
18 NC
ROI analysis of cortical and subcortical GM
MD (plus CTh and subcortical volumes)
Reduced MD (plus CTh) in precuneus, PCC +
parietotempral association cortices in PMCs
Widespread elevated MD in SMCs
Ryan et al. 2013 [38] Familial 10 PMC, 10 SMC,
20 NC
ROI MD and FA (GM and WM) + GM
volumes
In PMC, reduced MD in right hippocampus
(without atrophy) + cingulum, with increased
FA in thalamus and caudate. In SMCs MD rises
AD, Alzheimer’s disease; CTh, cortical thickness; DLB, Dementia with Lewy bodies; FA, fractional anisotropy; GM, grey matter; MCI, mild cognitive impairment; MD,
mean diffusivity; NC normal control; PCC, posterior cingulate cortex; PMC, presymptomatic mutation carrier; ROI, region of interest; SMC, symptomatic mutation
carrier; WM, white matter
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Whilst detection of grey matter diffusivity changes in AD
does show promise as a potential early biomarker, the
number and size of the studies performed to date is
relatively limited. Therefore, further replication of results,
ideally in large multicentre cohorts, will be very important.
One interesting and potentially useful direction of
investigation would be to develop a cortical 'signature'
of microstructural change for early AD, with the aim
of identifying a characteristic pattern of specific cortical
regions that undergo the earliest changes. This approach
has already been employed successfully for macrostruc-
tural measurements in AD [12].
Diffusion imaging may prove powerful in detecting
differences in underlying disease mechanisms, with one
study having already demonstrated significant differences
between different underlying neurodegenerative pathologies
[35]. Further studies of this type, where AD is comparedwith other disease processes rather than with healthy con-
trols only, are likely to improve our ability to differentiate
between different diseases in the clinical setting.
A further area of study that may improve sensitivity to
the earliest neurodegenerative changes in AD would be
the measurement of grey matter diffusivity across serial
MRI scans in order to assess longitudinal change. Meas-
urement of within-individual changes avoids between-
individual variability and may be a more sensitive and
relevant marker of pathological change than a single as-
sessment [52]. Tracking of within-individual longitudinal
change in diffusivity may also be useful when it comes to
presymptomatic, or early symptomatic, therapeutic trials.
Whilst it is unlikely that such trials will rely on any one
biomarker alone, with assessment of a combination of
different imaging, CSF and neuropsychometric measures
likely to be the optimal approach [53, 54], the potential
inclusion of grey matter diffusivity measurements could
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ment in combination with other molecular and neurodegen-
eration markers will also help improve our understanding of
how the timing of microstructural breakdown fits in
with other pathological changes.
The finding that MD initially decreases in the pre-
symptomatic stage of FAD [38, 39], prior to increasing
as microstructural breakdown occurs, warrants further
investigation in larger presymptomatic imaging studies,
as well as additional in vitro investigation to replicate
and ascertain the likely underlying mechanism.Conclusion
Diffusion imaging provides a means of assessing in vivo
microstructural changes in the brain; such changes are
likely to predate the macrostructural atrophy that char-
acterizes neurodegenerative disorders such as AD. The
most striking example of this is in CJD where diffusion
imaging of grey matter has proven to be a remarkably
sensitive and specific marker of disease. Diffusion changes
in grey matter in other, less rapidly progressive disorders
have been relatively understudied, but are increasingly of
interest in AD given that the earliest pathological changes
appear in grey matter in this disease and the growing
acceptance of a long prodromal period when molecular
pathology accumulates and yet cerebral atrophy can be
difficult to detect.
Grey matter diffusivity has shown initial promise in
the detection of early presymptomatic changes, as well
as in prediction of conversion from MCI to AD, and in
the differentiation of different dementia subtypes. Grey
matter structures commonly implicated, including the
hippocampus and posterior cingulate, have been identi-
fied as parts of a network vulnerable to early AD patho-
logical changes. Measuring diffusion changes in the grey
matter 'nodes' of these networks may provide information
that is complementary to the more studied changes in
white matter. However, whilst initial results appear posi-
tive, current literature is relatively limited, with findings
to date focusing on cross-sectional group changes only.
It is therefore true that a note of caution is required
when looking to the future. That said, magnetic reson-
ance diffusion acquisition capabilities and analytical
techniques are advancing rapidly. These advances offer
the prospect of grey matter diffusivity adding to our
understanding of the evolution of early changes in AD
and other neurodegenerative disorders - and contributing
to clinical diagnosis or providing inclusion or outcome
measures for trials.
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